ProUrokinase for Mild Ischemic Cerebrovascular Events (PUMICE)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1446 participants.

Also called NCT05507645

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,446 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05507645
Other papers using this trial's data
  • Prourokinase vs Standard Care for Patients With Mild Ischemic Stroke: The PUMICE Randomized Clinical Trial JAMA neurology, 2025-03-01 DOI, PubMed 39836393, PMC11894490 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05507645. Randomized; single masking; primary purpose treatment. Start 2022-11-15 (actual); primary completion 2024-03-26 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
ProUrokinase for Mild Ischemic Cerebrovascular Events (PUMICE)
Acronym
PUMICE
Condition
Mild
Condition
Thrombosis
Intervention (Drug)
Recombinant Human Prourokinase for Injection (rhPro-UK)
Intervention (Drug)
standard medical treatment
Lead sponsor
Beijing Tiantan Hospital (class: other)

Record details

Record id
cardio:ct-nct05507645
Content hash
395145434c91e926577d5b534e11006a4e294338368a64bf2e1906ec26a79a6f